CDK7 and neoplasm: CDK7‐based transcriptional targeting strategies have shown promising therapeutic effects in preclinical studies, particularly in refractory tumor types lacking conventional drug targets.[62, 63] Moreover, several CDK7 inhibitors have progressed to clinical trials (NCT03134638, NCT04247126, NCT03770494, and NCT03363893).